Brazilian National Research Ethics Commission (CONEP)

Brazilian National Research Ethics Commission (CONEP)
Name	Brazilian National Research Ethics Commission (CONEP)
Native name	Comissão Nacional de Ética em Pesquisa
Formed	1996
Headquarters	Brasília, Federal District
Parent organization	National Health Council
Jurisdiction	Brazil

Brazilian National Research Ethics Commission (CONEP) is the principal Brazilian agency charged with oversight of human subjects research and the ethical review of biomedical, social, and public health studies. Established within the National Health Council (Brazil), the commission coordinates ethical standards across federal institutions, universities, and research institutes such as Universidade de São Paulo, Fiocruz, and Universidade Federal do Rio de Janeiro. Its remit intersects with national laws like Brazilian Civil Registry matters, international instruments including the Declaration of Helsinki and the Nuremberg Code, and global bodies such as the World Health Organization.

History

CONEP was created in the aftermath of discussions involving actors such as the Ministry of Health (Brazil), Conselho Nacional de Saúde, and academic centers like Universidade Estadual de Campinas to implement protections comparable to those in the Belmont Report and the Council for International Organizations of Medical Sciences. Early deliberations referenced cases linked to institutions like Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and debates in the Federal Senate (Brazil). Major milestones included adoption of the first national resolution harmonized with the Declaration of Helsinki, alignment with the Pan American Health Organization guidelines, and later updates reflecting rulings by the Supremo Tribunal Federal and regulatory shifts related to the Lei de Biossegurança.

Structure and Governance

CONEP operates as a collegiate body under the Ministry of Health (Brazil) via the National Health Council (Brazil), comprising appointed representatives from entities such as Universidade de Brasília, Universidade Federal de Minas Gerais, Fundação Oswaldo Cruz, patient advocacy groups like Associação Brasileira de Defesa do Consumidor, and professional societies including the Associação Médica Brasileira and Sociedade Brasileira de Bioética. Governance involves an executive secretariat, technical chambers modeled on committees like those in Instituto Nacional de Câncer (INCA), and liaison roles with regional Comitês de Ética em Pesquisa and institutional review boards at centers such as Hospital Sírio-Libanês and Hospital das Clínicas da Universidade Federal de Minas Gerais. Legal oversight references statutes including the Constituição da República Federativa do Brasil and norms set by the Ministério da Saúde.

Functions and Responsibilities

CONEP’s mandate includes reviewing protocols for clinical trials sponsored by entities like Anvisa, pharmaceutical firms such as Fiocruz, and multinational companies operating under agreements with institutions like Universidade Federal do Rio Grande do Sul. Responsibilities encompass issuing ethical opinions on studies involving vulnerable populations from regions like the Amazonas (state), indigenous groups referenced in policies from Fundação Nacional do Índio, and public health interventions in collaboration with the Secretaria de Vigilância em Saúde. It sets standards for informed consent procedures influenced by precedents from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, adjudicates conflicts invoking precedents from the Supremo Tribunal Federal, and promulgates directives that affect biomedical research at centers such as Instituto Butantan.

Ethical Review Process

The ethical review process administered by CONEP follows stages similar to review systems in agencies like the National Institutes of Health and the European Medicines Agency: initial protocol submission, risk–benefit assessment, continuing review, and adverse event reporting. Protocols from investigators at universities such as Universidade Federal de São Paulo must pass through institutional Comitês de Ética em Pesquisa before escalation to CONEP for high-risk categories including gene therapy trials paralleling work at Instituto de Biologia Molecular do Paraná and vaccine trials akin to studies by Fiocruz. Reviews reference international frameworks like the Council of Europe bioethics instruments and coordinate with regulatory bodies including Agência Nacional de Vigilância Sanitária for pharmacovigilance, while requiring documentation comparable to submissions to the Food and Drug Administration for investigational products.

Policy Impact and Regulations

CONEP’s decisions have shaped national norms such as the Resolução CNS nº 466/2012 and influenced regulatory practice at agencies like Anvisa. Its guidance has affected research funding rules at agencies including the Conselho Nacional de Desenvolvimento Científico e Tecnológico and compliance expectations for programs sponsored by the Brazilian Ministry of Science, Technology and Innovation. By aligning Brazilian standards with instruments like the International Ethical Guidelines for Health-related Research from the Council for International Organizations of Medical Sciences and collaborating with organizations such as the World Medical Association, CONEP contributed to harmonization that impacts multinational clinical trials involving sponsors such as Pfizer and research partnerships with institutions like Harvard University and Johns Hopkins University.

Controversies and Criticisms

CONEP has faced controversies involving high-profile trials and ethical disputes that drew attention from outlets like Supremo Tribunal Federal deliberations and scrutiny from academic critics at Universidade de São Paulo and Universidade Estadual de Campinas. Criticisms include perceived delays in protocol review affecting trial timelines for vaccines developed in partnership with entities such as Fiocruz and Butantan Institute, disputes over consent in research involving indigenous communities represented by Fundação Nacional do Índio, and tensions with multinational sponsors including GlaxoSmithKline regarding regulatory requirements. Debates have invoked comparative controversies like historical cases reviewed under the Nuremberg Code and policy dialogues with the World Health Organization, prompting calls for reform by stakeholder groups including patient advocacy organizations and professional societies such as the Sociedade Brasileira de Bioética.

Category:Health in Brazil